Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from Georgetown University.
2449 articles by Ned Pagliarulo
-
Bristol Myers to cut 6% of workforce, trim drug pipeline
April 25, 2024 -
Moderna turns to AI to change how its employees work
April 24, 2024 -
Novartis raises forecasts as top drug sales beat Wall Street estimates
April 23, 2024 -
Bristol Myers taps startup to boost cell therapy production
April 22, 2024 -
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
April 18, 2024 -
J&J sees mixed performance from new multiple myeloma drugs
April 16, 2024 -
Ultragenyx says Angelman therapy is working, but safety questions remain
April 15, 2024 -
FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use
April 5, 2024 -
Merck puts KRAS cancer drug competitor to the test
April 4, 2024 -
Verve pauses base editing trial, shifts strategy after treatment side effect
April 2, 2024 -
Gilead bets on Xilio cancer drug as biotech restructures
March 28, 2024 -
Stoke shares surge on updated results for Dravet drug
March 26, 2024 -
Novo to acquire heart failure drug in $1B deal for Cardior
March 25, 2024 -
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
Feb. 29, 2024 -
Janux shares triple on early cancer immunotherapy data
Feb. 27, 2024 -
Minerva schizophrenia drug rejected by FDA
Feb. 27, 2024 -
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
Feb. 23, 2024 -
Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’
Feb. 22, 2024 -
AstraZeneca gets new Tagrisso OK as drug succeeds in another trial
Feb. 20, 2024 -
Ipsen drug approved by FDA for early pancreatic cancer
Feb. 14, 2024 -
Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex
Feb. 14, 2024 -
Gilead to buy CymaBay in $4.3B deal for liver disease drug
Feb. 12, 2024 -
Obesity drug mania takes over Amgen’s earnings call
Feb. 7, 2024 -
Merck keeps deal focus with Keytruda patent cliff on horizon
Feb. 1, 2024 -
New CMS pilot to test payment scheme for pricey sickle cell gene therapies
Jan. 31, 2024